Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2023-01-19 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
关于股东部分股份质押的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the pledge of shares by a major shareholder of the company. It details the number of shares pledged, the proportion of shares involved, the pledge period, and the pledgee. It also states that the pledge does not affect the company's control or operations. There is no financial report, earnings data, or management discussion. The document is a regulatory announcement about a shareholder's share pledge, which fits the category of Capital/Financing Update (CAP) as it relates to financing activities involving share pledges.
2023-01-19 Chinese
2022年度业绩预告
Earnings Release Classification · 95% confidence The document is titled as a '2022年度业绩预告' which translates to '2022 Annual Performance Forecast'. It provides estimated net profit figures for the full year 2022 and compares them to the previous year. It explicitly states that the financial data is preliminary, unaudited, and that the detailed audited figures will be disclosed in the 2022 Annual Report. The document length is short (1181 characters) and it is a forward-looking earnings forecast rather than an actual financial report. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. It is not a full Annual Report (10-K) or Interim Report (IR) because it lacks audited financial statements and detailed analysis. It is not a Report Publication Announcement (RPA) because it contains substantive financial forecast data, not just a notice of report availability. Therefore, the correct classification is Earnings Release (ER). FY 2022
2023-01-10 Chinese
关于重组人生长激素-Fc融合蛋白注射液获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding the receipt of a drug clinical trial approval notice from the National Medical Products Administration. It details the approval for clinical trials of a recombinant human growth hormone-Fc fusion protein injection. The content focuses on regulatory approval and clinical trial initiation, not financial results, management changes, or shareholder information. The document length is short (1025 characters) and it is an official announcement about regulatory approval, not a financial report or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-12-29 Chinese
关于全资子公司通过高新技术企业认定的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (566 characters) from Anhui Anke Bioengineering (Group) Co., Ltd. regarding its wholly-owned subsidiary Anhui Anke Hengyi Pharmaceutical Co., Ltd. being recognized as a high-tech enterprise and receiving a certificate. It includes details about the certificate number, issue date, and tax benefits. There is no financial data, no report attached or referenced as being published, and no mention of a meeting or voting results. The document is an official announcement about a regulatory recognition and related tax policy benefits, which does not fit into financial reports or management reports categories. It is a regulatory announcement about a certification and tax status. Therefore, it best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories. Confidence is high due to clear content and short length indicating an announcement rather than a report.
2022-12-28 Chinese
2022年第三次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2022 third extraordinary general meeting of shareholders of Anhui Anke Biological Engineering (Group) Co., Ltd. It includes information about the meeting date, attendance, voting results for board and supervisory board elections, and legal opinions confirming the validity of the meeting and resolutions. There is no financial data or report content, but rather the official voting results and decisions made at the shareholders meeting. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)'. The document length is under 5,000 characters and contains detailed voting results, not just a brief announcement or a report publication notice. Therefore, the correct classification is DVA with high confidence.
2022-12-23 Chinese
关于第八届董事会第一次会议决议的公告
Board/Management Information Classification · 100% confidence The document is an announcement from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding the resolutions of the first meeting of the eighth board of directors. It details the election and appointment of board members, senior management, and committee members, including their resumes and voting results. The content focuses on changes and appointments in the company's board and senior management, with no financial statements or financial performance data included. The document length is 6792 characters, which is sufficient for a detailed announcement but does not contain financial reports or earnings data. Therefore, this document fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2022-12-23 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.